Target family: Class A Orphans (type: gpcr)
Target: <i>GPR35</i>

Ligand: zaprinast (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 7.8 pEC50
Reference (Journal): Zaprinast, a well-known cyclic guanosine monophosphate-specific phosphodiesterase inhibitor, is an agonist for GPR35.
Published in: FEBS Lett

Ligand: zaprinast (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 6.1 pEC50
Reference (Journal): Zaprinast, a well-known cyclic guanosine monophosphate-specific phosphodiesterase inhibitor, is an agonist for GPR35.
Published in: FEBS Lett

Ligand: pamoic acid (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 7.29 pEC50
Reference (Journal): Identification of novel species-selective agonists of the G-protein-coupled receptor GPR35 that promote recruitment of β-arrestin-2 and activate Gα13.
Published in: Biochem J

Ligand: pamoic acid (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  pEC50
Reference (Journal): Identification of novel species-selective agonists of the G-protein-coupled receptor GPR35 that promote recruitment of β-arrestin-2 and activate Gα13.
Published in: Biochem J

Ligand: lodoxamide (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: UK (1991), FDA (1993)
Primary target: no
Median affinity: 9 pEC50
Reference (Journal): GPR35 mediates lodoxamide-induced migration inhibitory response but not CXCL17-induced migration stimulatory response in THP-1 cells; is GPR35 a receptor for CXCL17?
Published in: Br J Pharmacol

Ligand: kynurenic acid (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  pEC50
Reference (Journal): Screening β-Arrestin Recruitment for the Identification of Natural Ligands for Orphan G-Protein-Coupled Receptors.
Published in: J Biomol Screen

Ligand: kynurenic acid (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  pEC50
Reference (Journal): Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35.
Published in: J Biol Chem

Ligand: kynurenic acid (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 5.15 pEC50
Reference (Journal): Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35.
Published in: J Biol Chem

Ligand: kynurenic acid (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 4.96 pEC50
Reference (Journal): Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35.
Published in: J Biol Chem

Ligand: furosemide (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (1966)
Median affinity:  pEC50
Reference (Journal): GPR35 is a target of the loop diuretic drugs bumetanide and furosemide.
Published in: Pharmacology

Ligand: CXCL17 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Cutting edge: GPR35/CXCR8 is the receptor of the mucosal chemokine CXCL17.
Published in: J Immunol

Ligand: compound 83 [PMID: 23888932] (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 9.229999542236328 pKi
Reference (Journal): 6-Bromo-8-(4-[(3)H]methoxybenzamido)-4-oxo-4H-chromene-2-carboxylic Acid: a powerful tool for studying orphan G protein-coupled receptor GPR35.
Published in: J Med Chem

Ligand: CID2745687 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 7.369999885559082 pKi
Reference (Journal): 6-Bromo-8-(4-[(3)H]methoxybenzamido)-4-oxo-4H-chromene-2-carboxylic Acid: a powerful tool for studying orphan G protein-coupled receptor GPR35.
Published in: J Med Chem

Ligand: CID2745687 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 6.699999809265137 pIC50
Reference (Journal): 6-Bromo-8-(4-[(3)H]methoxybenzamido)-4-oxo-4H-chromene-2-carboxylic Acid: a powerful tool for studying orphan G protein-coupled receptor GPR35.
Published in: J Med Chem

Ligand: CID2745687 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 4.980000019073486 pIC50
Reference (Journal): 6-Bromo-8-(4-[(3)H]methoxybenzamido)-4-oxo-4H-chromene-2-carboxylic Acid: a powerful tool for studying orphan G protein-coupled receptor GPR35.
Published in: J Med Chem

Ligand: CID2745687 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 7.889999866485596 pKi
Reference (Journal): Targeting of the orphan receptor GPR35 by pamoic acid: a potent activator of extracellular signal-regulated kinase and β-arrestin2 with antinociceptive activity.
Published in: Mol Pharmacol

Ligand: bumetanide (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (1983)
Median affinity:  pEC50
Reference (Journal): GPR35 is a target of the loop diuretic drugs bumetanide and furosemide.
Published in: Pharmacology

Ligand: 2-oleoyl-LPA (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  pEC50
Reference (Journal): GPR35 is a novel lysophosphatidic acid receptor.
Published in: Biochem Biophys Res Commun